Peter Griffiths

Syniti enables agile enterprises with silo-free enterprise data management that helps turn complex data challenges into competitive advantages. With a unified, learning platform and one of the world’s largest teams of data-focused experts, enterprises and global alliance partners choose Syniti when they require trusted data to ignite business growth and reduce risks. Syniti is a portfolio company of BridgeGrowth Partners LLC. Headquartered in Boston, Massachusetts with offices in 25 countries around the world, Syniti operates in all global regions and industry verticals, and maintains a 99.7% client success rate across thousands of complex data projects and initiatives.

Aria Pharmaceuticals is a preclinical-stage pharmaceutical company discovering and developing novel small molecule therapies for complex and hard-to-treat diseases. Too many patients today are in need of breakthrough treatments across many complicated diseases – they can’t wait. That’s why at Aria, we have redefined the drug discovery approach, saving years in the process and increasing success rates 30 times higher than traditional methods. At Aria, we’ve shown promise across a diverse range of therapeutic areas with the ability to address over 1,000 diseases.

Bridge Growth Partner, LLC is a private equity firm that targets investments in the technology and technology-enabled services sectors.

Syniti enables agile enterprises with silo-free enterprise data management that helps turn complex data challenges into competitive advantages. With a unified, learning platform and one of the world’s largest teams of data-focused experts, enterprises and global alliance partners choose Syniti when they require trusted data to ignite business growth and reduce risks. Syniti is a portfolio company of BridgeGrowth Partners LLC. Headquartered in Boston, Massachusetts with offices in 25 countries around the world, Syniti operates in all global regions and industry verticals, and maintains a 99.7% client success rate across thousands of complex data projects and initiatives.

Accedian is the leader in performance analytics and end user experience solutions, dedicated to providing our customers with the ability to assure their digital infrastructure, while helping them to unlock the full productivity of their users. We are committed to empowering our customers with the ability to see far and wide across their IT and network infrastructure and a microscopic ability to dive deep and understand the experience of every user, helping them to delight their own customers each and every time. The Accedian Skylight™ performance management platform scales to monitor multinational networks and hundreds of millions of users. Accedian is an established expert at instrumenting networks of every size, providing a universal view of performance across all applications, functions, links, and components for hybrid, dynamic, multi-vendor infrastructures. Accedian has been delivering solutions to high profile customers globally for over 15 years. For more information, visit accedian.com. Twitter: @Accedian

Aria Pharmaceuticals is a preclinical-stage pharmaceutical company discovering and developing novel small molecule therapies for complex and hard-to-treat diseases. Too many patients today are in need of breakthrough treatments across many complicated diseases – they can’t wait. That’s why at Aria, we have redefined the drug discovery approach, saving years in the process and increasing success rates 30 times higher than traditional methods. At Aria, we’ve shown promise across a diverse range of therapeutic areas with the ability to address over 1,000 diseases.

Mistral is a seed stage venture capital firm and typically the first institutional investor in our companies. We have offices in Ottawa and Toronto.